Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice - PubMed (original) (raw)
Comparative Study
Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice
J Gisby et al. Antimicrob Agents Chemother. 1991 May.
Abstract
Experimental respiratory infections were established in mice by intranasal inoculation of Streptococcus pneumoniae. Inoculation of 10(7) CFU of either S. pneumoniae 1629 or S. pneumoniae 7 produced a fatal pneumonia in nontreated mice 2 to 3 days after infection. Oral therapy was commenced 1 h after infection and was continued three times a day for 2 days. The doses used in mice produced peak concentrations in serum and lung tissue similar to those measured in humans. Ciprofloxacin failed to eliminate either strain of pneumococcus from mouse lungs at any of the doses tested (40, 80, or 160 mg/kg of body weight) by the end of therapy (33 h). Mice that received ciprofloxacin at 160 mg/kg were clear of S. pneumoniae 7 5 days later, whereas persistence and regrowth of S. pneumoniae 1629 resulted in the death of 20% of animals treated with ciprofloxacin. Therapy with cefaclor (20 mg/kg) produced an effect similar to that of ciprofloxacin. In contrast, amoxicillin (10 and 20 mg/kg) and amoxicillin-clavulanic acid (10/5 and 20/10 mg/kg) were significantly (P less than 0.05) more effective in eliminating both strains of S. pneumoniae from the lungs by the end of therapy and, by 168 h, had prevented mortality in 80 to 100% of treated animals. The efficacy of ciprofloxacin against these experimental pneumococcal respiratory infections was poor, despite good penetration into lung tissue, and is a reflection of the low in vitro activity of the quinolone against S. pneumoniae, one of the most common pathogens in community-acquired pneumonia.
Similar articles
- Influence of clavulanic acid on the activity of amoxicillin against an experimental Streptococcus pneumoniae-Staphylococcus aureus mixed respiratory infection.
Smith GM, Boon RJ, Beale AS. Smith GM, et al. Antimicrob Agents Chemother. 1990 Feb;34(2):210-4. doi: 10.1128/AAC.34.2.210. Antimicrob Agents Chemother. 1990. PMID: 2327767 Free PMC article. - In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
Blandino G, Aleo G, Caccamo F, Nicolosi VM, Siracusa V, Speciale A. Blandino G, et al. J Chemother. 1996 Jun;8(3):193-9. doi: 10.1179/joc.1996.8.3.193. J Chemother. 1996. PMID: 8808715 - [Bactericide activity of cefadroxil comparated with amoxicillin-clavulanic acid, cefaclor and josamycin].
Etesse-Carsenti H, Caillon J, Mondain V, Durant J, Bernard E, Dellamonica P, Drugeon HB. Etesse-Carsenti H, et al. Pathol Biol (Paris). 1991 Sep;39(7):658-67. Pathol Biol (Paris). 1991. PMID: 1758716 French. - Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Todd PA, Benfield P. Todd PA, et al. Drugs. 1990 Feb;39(2):264-307. doi: 10.2165/00003495-199039020-00008. Drugs. 1990. PMID: 2184003 Review. - Overview of newer antimicrobial formulations for overcoming pneumococcal resistance.
Craig WA. Craig WA. Am J Med. 2004 Aug 2;117 Suppl 3A:16S-22S. doi: 10.1016/j.amjmed.2004.07.004. Am J Med. 2004. PMID: 15360093 Review.
Cited by
- Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.
Abgueguen P, Azoulay-Dupuis E, Noel V, Moine P, Rieux V, Fantin B, Bedos JP. Abgueguen P, et al. Antimicrob Agents Chemother. 2007 Jan;51(1):208-14. doi: 10.1128/AAC.00004-06. Epub 2006 Oct 23. Antimicrob Agents Chemother. 2007. PMID: 17060515 Free PMC article. - Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.
Conte JE Jr, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E. Conte JE Jr, et al. Antimicrob Agents Chemother. 1996 Jul;40(7):1617-22. doi: 10.1128/AAC.40.7.1617. Antimicrob Agents Chemother. 1996. PMID: 8807050 Free PMC article. - Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.
Bonacorsi SP, Scavizzi MR, Guiyoule A, Amouroux JH, Carniel E. Bonacorsi SP, et al. Antimicrob Agents Chemother. 1994 Mar;38(3):481-6. doi: 10.1128/AAC.38.3.481. Antimicrob Agents Chemother. 1994. PMID: 8203841 Free PMC article. - Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.
Sullivan MC, Cooper BW, Nightingale CH, Quintiliani R, Lawlor MT. Sullivan MC, et al. Antimicrob Agents Chemother. 1993 Feb;37(2):234-9. doi: 10.1128/AAC.37.2.234. Antimicrob Agents Chemother. 1993. PMID: 8452353 Free PMC article. - Quinolones in the treatment of lower respiratory tract infections in adult patients.
Carbon C. Carbon C. Drugs. 1993;45 Suppl 3:91-7. doi: 10.2165/00003495-199300453-00016. Drugs. 1993. PMID: 7689458 Review.
References
- Am J Med. 1989 Oct;87(4):475 - PubMed
- Int J Clin Pharmacol Ther Toxicol. 1989 Jan;27(1):30-3 - PubMed
- Antimicrob Agents Chemother. 1986 Jun;29(6):1088-9 - PubMed
- Eur J Clin Microbiol. 1986 Apr;5(2):226-31 - PubMed
- Clin Ther. 1988;11 Suppl A:5-19 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical